Edition:
United States

Ritter Pharmaceuticals Inc (RTTR.OQ)

RTTR.OQ on NASDAQ Stock Exchange Capital Market

0.70USD
3:59pm EST
Change (% chg)

$-0.05 (-6.04%)
Prev Close
$0.75
Open
$0.75
Day's High
$0.75
Day's Low
$0.67
Volume
7,940
Avg. Vol
16,786
52-wk High
$3.99
52-wk Low
$0.67

Latest Key Developments (Source: Significant Developments)

Ritter Pharmaceuticals Q3 Loss Per Share $0.86
Friday, 9 Nov 2018 07:00am EST 

Nov 9 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 AND RECENT PROGRESS.Q3 LOSS PER SHARE $0.86.Q3 EARNINGS PER SHARE VIEW $-0.78 -- THOMSON REUTERS I/B/E/S.  Full Article

Ritter Pharmaceuticals Announces 1-For-10 Reverse Stock Split
Thursday, 22 Mar 2018 11:35am EDT 

March 22 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.RITTER PHARMACEUTICALS INC - ‍ANNOUNCED A 1-FOR-10 REVERSE SPLIT OF ITS COMMON STOCK, PAR VALUE $0.001 PER SHARE EFFECTIVE MARCH 23, 2018​.  Full Article

Ritter Pharmaceuticals Reports Q4 Loss Per Share $0.11
Monday, 19 Mar 2018 06:34am EDT 

March 19 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.11.‍ ON TRACK TO START SCREENING IN Q2​ FOR FIRST PIVOTAL PHASE 3 CLINICAL TRIAL OF RP-G28 IN LACTOSE INTOLERANCE.‍ AS OF DECEMBER 31, 2017, HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $22.6 MILLION​.  Full Article

Ritter Pharmaceuticals Reports Microbiome Data From Phase 2B Study Of RP-G28 Promotes Beneficial Adaptation Of The Gut Microbiome
Monday, 12 Mar 2018 06:00am EDT 

March 12 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS REPORTS MICROBIOME DATA FROM PHASE 2B STUDY OF RP-G28 PROMOTES BENEFICIAL ADAPTATION OF THE GUT MICROBIOME.RITTER PHARMACEUTICALS INC - ‍DURING PHASE 2A STUDY, OBSERVED AN INCREASE IN BIFIDOBACTERIA, WHICH WERE CONFIRMED IN LARGER PHASE 2B STUDY​.RITTER PHARMACEUTICALS INC - ‍PHASE 3 CLINICAL TRIAL OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE IN Q2 2018​.  Full Article

‍sabby Management reports 9.94 pct passive stakee in Ritter Pharmaceuticals
Tuesday, 3 Oct 2017 01:34pm EDT 

Oct 3 (Reuters) - Ritter Pharmaceuticals Inc :‍sabby Management, LLC​ reports 9.94 percent passive stakee in Ritter Pharmaceuticals Inc as of September 29 - sec filing.  Full Article

RITTER PHARMA RAISES $23 MLN TO FUND PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE
Tuesday, 3 Oct 2017 12:00pm EDT 

Oct 3 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS, INC. RAISES $23 MILLION TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE.PROCEEDS WILL ALLOW CO TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE.‍PHASE 3 CLINICAL PROGRAM OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE EXPECTED TO BEGIN IN FIRST HALF OF 2018​.  Full Article

Ritter Pharmaceuticals Inc prices $23,000,000 public offering
Friday, 29 Sep 2017 08:00am EDT 

Sept 29 (Reuters) - Ritter Pharmaceuticals Inc :Ritter Pharmaceuticals, Inc. prices $23,000,000 public offering.Ritter Pharmaceuticals Inc - offering is expected to close on October 3, 2017.  Full Article

Ritter Pharma announces Phase 3 plans after end of Phase 2 meeting with FDA on RP-G28
Friday, 18 Aug 2017 09:30am EDT 

Aug 18 (Reuters) - Ritter Pharmaceuticals Inc ::Ritter Pharmaceuticals announces Phase 3 plans after its end of Phase 2 meeting with FDA on RP-G28 for lactose intolerance.Has incorporated guidance from FDA on key elements of its phase 3 program to support a new drug application (NDA) for RP-G28.Company anticipates initiating phase 3 program during first half of 2018​.  Full Article

Ritter Pharmaceuticals reports further analysis from its phase 2b/3 trial results demonstrating significant reductions in lactose intolerance symptoms
Thursday, 3 Aug 2017 09:30am EDT 

Aug 3 (Reuters) - Ritter Pharmaceuticals Inc :Ritter Pharmaceuticals reports further analysis from its phase 2b/3 trial results demonstrating significant reductions in lactose intolerance symptoms.Ritter Pharmaceuticals - ‍Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world assessments​.Ritter Pharmaceuticals- ‍treatment effect suggests clinically meaningful benefit to subjects in significantly reducing symptoms of lactose intolerance​.Ritter Pharmaceuticals Inc - Study demonstrated safety with no serious adverse events related to treatment.Ritter Pharmaceuticals Inc- ‍Company has been granted an end of phase 2 meeting with FDA, which will take place by end of 2017​.Ritter Pharmaceuticals Inc - Company has also commenced manufacturing efforts and plans to commence phase 3 clinical program in first half of 2018.Ritter Pharmaceuticals- ‍In preparation for phase 3 program, also commenced manufacturing efforts, plans to commence phase 3 clinical program in 1H 2018​.  Full Article

Ritter pharmaceuticals files for offering of up to $10 mln ‍​
Monday, 3 Jul 2017 05:34pm EDT 

July 3 (Reuters) - Ritter Pharmaceuticals Inc ::Ritter Pharmaceuticals files for offering of up to $10 million of class a units consisting of stock and warrants and class b units consisting of preferred stock & warrants ‍​.  Full Article